Publications by authors named "S Ohwada"
Article Synopsis
- * Two Phase 1b studies conducted in Japan and China tested the safety and effectiveness of quizartinib combined with standard chemotherapy, starting at a low dose of 20 mg/day and increasing to 40 mg/day without significant toxicity.
- * The studies found no major dose-limiting side effects, although some patients experienced serious adverse events, confirming that the drug's pharmacokinetics are similar in Asian populations as previously reported in the U.S.
Purpose: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HER3-expressing advanced breast cancer in the U31402-A-J101 study.
Methods: Adults with disease progression on previous therapies were eligible.
We report a case of diverticulum of the buccal mucosa. A 56-year-old man had a small pouch-shaped lesion behind the parotid papilla that caused pain and food impaction. After resection, the lesion was histopathologically diagnosed as diverticulum without buccal muscle tear.
View Article and Find Full Text PDF